<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087295</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000373886</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S0400</secondary_id>
    <nct_id>NCT00087295</nct_id>
  </id_info>
  <brief_title>S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium</brief_title>
  <official_title>A Phase II Study of Depsipeptide (NSC-630176) In Patients With Advanced Transitional Cell Carcinoma Of The Urinary Tract Who Have Progressed After Receiving One Prior Chemotherapy Regimen For Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as FR901228 (depsipeptide), work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with&#xD;
      advanced cancer of the urothelium that has progressed or recurred after receiving one&#xD;
      chemotherapy regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response (confirmed complete and partial) in patients with advanced&#xD;
           transitional cell carcinoma of the urothelium that has progressed after prior&#xD;
           chemotherapy when treated with FR901228 (depsipeptide) .&#xD;
&#xD;
        -  Determine progression-free and overall survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the effects of this drug on reversing tumor promoter gene&#xD;
           methylation in these patients.&#xD;
&#xD;
        -  Correlate, preliminarily, tumor DNA in plasma with response or outcome in patients&#xD;
           treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving a complete response receive 2 additional courses of treatment.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Permanently Closed Due to Poor Accrual&#xD;
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of response (confirmed complete and partial)</measure>
    <time_frame>From date of registration to progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of registration to progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of registration to progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and grade of adverse events</measure>
    <time_frame>From date of registration to progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Urethral Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depsipeptide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depsipeptide</intervention_name>
    <description>Depsipeptide wil be given 13 mg/m^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>FR901228</other_name>
    <other_name>FK228</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma of the urothelium (bladder, renal&#xD;
             pelvis, ureter, or urethra)&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
                    -  Node-positive, non-metastatic disease that is unresectable is allowed&#xD;
&#xD;
               -  Poorly differentiated transitional cell carcinoma OR predominant transitional&#xD;
                  cell carcinoma with rare foci of squamous differentiation or rare foci of&#xD;
                  adenocarcinoma allowed&#xD;
&#xD;
          -  The following histologic types are not allowed:&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Small cell carcinoma&#xD;
&#xD;
               -  Sarcoma&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Mixed adeno/squamous/transitional histology&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 2 cm by conventional techniques&#xD;
                  OR ≥ 1 cm by spiral CT scan&#xD;
&#xD;
               -  Soft tissue disease irradiated within the past 2 months is not considered&#xD;
                  measurable&#xD;
&#xD;
          -  Disease progression or recurrence after 1, and only 1, prior systemic chemotherapy&#xD;
             regimen that included cisplatin or carboplatin for metastatic disease&#xD;
&#xD;
          -  Not curable by surgery or radiotherapy&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  White blood cell (WBC) count ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Aspartate aminotransferase (SGOT) / alanine aminotransferase (SGPT) ≤ 2.5 times upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Corrected QT interval (QTc) &lt; 500 msec&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt; 40% by Multi Gated Acquisition Scan (MUGA)&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled dysrhythmias&#xD;
&#xD;
          -  No poorly controlled angina&#xD;
&#xD;
          -  No serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation&#xD;
             ≥ 3 beats in a row)&#xD;
&#xD;
          -  No left ventricular hypertrophy on EKG&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Potassium ≥ 4 mmol/L&#xD;
&#xD;
          -  Magnesium ≥ 2 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biological composition&#xD;
             to FR901228 (depsipeptide)&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer in complete remission&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
          -  No prior FR901228 (depsipeptide)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 28 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 28 days since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 28 days since prior intravesical therapy&#xD;
&#xD;
          -  No concurrent hydrochlorothiazide&#xD;
&#xD;
          -  No concurrent agent that causes QTc prolongation&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational histone deacetylase inhibitor agents or drugs&#xD;
             (e.g., sodium valproate)&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P. Petrylak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>recurrent transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>recurrent urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

